Pipeline of Polycythemia Vera Market Reviewed for H1 2016

PUNE, India, April 14, 2016 /PRNewswire/ --

RnRMarketResearch.com adds new market research titled "Polycythemia Vera - Pipeline Review, H1 2016" to its store. The report provides an overview of the Polycythemia Vera's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this report includes Bristol-Myers Squibb Company, Galena Biopharma, Inc., Gilead Sciences, Inc., Italfarmaco S.p.A., Karus Therapeutics Limited, Merck & Co., Inc., miRagen Therapeutics, Inc., Nerviano Medical Sciences S.r.l., Novartis AG and PharmaEssentia Corporation. Drugs Profiles discussed in this research includes anagrelide hydrochloride CR, dasatinib, givinostat, idelalisib, KA-1463, M-009, M-012, MGN-4893, MRLB-11055, NMSP-113, ropeginterferon alfa-2b and sonidegib phosphate.

Complete report on H1 2016 pipeline review of Polycythemia Vera with 24 market data tables and 12 figures, spread across 75 pages is available at http://www.rnrmarketresearch.com/polycythemia-vera-pipeline-review-h1-2016-market-report.html .

This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera and reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Polycythemia Vera.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=525939 .

List of Tables: 

Number of Products under Development for Polycythemia Vera, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Polycythemia Vera Therapeutics - Recent Pipeline Updates, H1 2016

Polycythemia Vera - Dormant Projects, H1 2016

Polycythemia Vera - Discontinued Products, H1 2016

Another newly published market research report titled on Anal Cancer - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies discussed in this pipeline research are Advaxis, Inc., Amgen Inc., Eli Lilly and Company, Genticel S.A., ISA Pharmaceuticals B.V., Novartis AG, Oryx GmbH & Co. KG, PDS Biotechnology Corporation, Sun Pharma Advanced Research Company Ltd. and Taiwan Liposome Company, Ltd. Anal Cancer Pipeline market research report of 86 pages is available at http://www.rnrmarketresearch.com/anal-cancer-pipeline-review-h1-2016-market-report.html .

Explore more reports on Cancer Therapeutics.

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:  

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com